down arrow

RVL Pharmaceuticals Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IE00BF2HDL56
USD
0.00
0.00 (0.00%)

Dec 03

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.00
Valuation
Technical
Day's Volume

CASH

1

Shareholding (Dec 2023)

FII

0.26%

Held by 8 FIIs

DII

97.2%

Held by 5 DIIs

Promoter

0.57%

How big is RVL Pharmaceuticals Plc?

22-Jun-2025

As of Jun 18, RVL Pharmaceuticals Plc has a market capitalization of 0.00, classifying it as a Micro Cap company. For the latest four quarters, it reported net sales of 36.92 million and a net profit of -68.27 million, with shareholder's funds of 51.09 million and total assets of 135.38 million as of Dec 22.

As of Jun 18, RVL Pharmaceuticals Plc has a market capitalization of 0.00, categorizing it as a Micro Cap company.<BR><BR>As of Jun 23, the company reported net sales of 36.92 million for the latest four quarters. However, it also recorded a net profit of -68.27 million during the same period.<BR><BR>As of Dec 22, the balance sheet shows shareholder's funds of 51.09 million and total assets amounting to 135.38 million.

Read More

Who are in the management team of RVL Pharmaceuticals Plc?

22-Jun-2025

As of March 2022, the management team of RVL Pharmaceuticals Plc includes Mr. Brian Markison (Chairman and CEO), Mr. Joachim Benes, Mr. David Burgstahler, Mr. Sriram Venkataraman, Mr. Juan Vergez, and Mr. Gregory Cowan (Independent Director). They oversee the company's operations and strategic direction.

As of March 2022, the management team of RVL Pharmaceuticals Plc includes the following individuals:<BR><BR>- Mr. Brian Markison, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Joachim Benes, Director.<BR>- Mr. David Burgstahler, Director.<BR>- Mr. Sriram Venkataraman, Director.<BR>- Mr. Juan Vergez, Director.<BR>- Mr. Gregory Cowan, Independent Director. <BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is RVL Pharmaceuticals Plc technically bullish or bearish?

20-Sep-2025

As of November 25, 2024, RVL Pharmaceuticals Plc shows a mildly bearish technical trend with conflicting signals, underperforming the S&P 500 significantly over the past 3, 5, and 10 years.

As of 25 November 2024, the technical trend for RVL Pharmaceuticals Plc has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The RSI shows no signal on both weekly and monthly time frames, and Bollinger Bands are sideways, indicating a lack of volatility. Overall, the technical stance is mildly bearish. <BR><BR>In terms of multi-period returns, RVL Pharmaceuticals has underperformed significantly compared to the S&P 500 over the 3-year, 5-year, and 10-year periods, with returns of -100% versus the S&P 500's gains of 70.41%, 96.61%, and 231.64%, respectively.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

2.38

stock-summary
Return on Equity

-229.87%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Jun 2023)
Net Profit:
-24 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

RVL Pharmaceuticals Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is RVL Pharmaceuticals Plc technically bullish or bearish?

As of 25 November 2024, the technical trend for RVL Pharmaceuticals Plc has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The RSI shows no signal on both weekly and monthly time frames, and Bollinger Bands are sideways, indicating a lack of volatility. Overall, the technical stance is mildly bearish. In terms of multi-period returns, RVL Pharmaceuticals has underperformed significantly compared to the S&P 500 over the 3-year, 5-year, and 10-year periods, with returns of -100% versus the S&P 500's gains of 70.41%, 96.61%, and 231.64%, respectively....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-37.80%
EBIT Growth (5y)
-195.74%
EBIT to Interest (avg)
-11.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.38
Sales to Capital Employed (avg)
0.45
Tax Ratio
0.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
23.91%
ROCE (avg)
0.69%
ROE (avg)
0.94%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
-0.89
EV to EBITDA
-0.90
EV to Capital Employed
0.70
EV to Sales
1.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-79.05%
ROE (Latest)
-229.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 8 Schemes (1.97%)

Foreign Institutions

Held by 8 Foreign Institutions (0.26%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2023 is -1.19% vs -26.96% in Jun 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2023 is -97.52% vs 45.00% in Jun 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Jun'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.30",
          "val2": "8.40",
          "chgp": "-1.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.00",
          "val2": "-15.00",
          "chgp": "46.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.00",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-16.20",
          "val2": "4.20",
          "chgp": "-485.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.90",
          "val2": "-12.10",
          "chgp": "-97.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-983.40%",
          "val2": "-1,790.20%",
          "chgp": "80.68%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 184.00% vs -37.05% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 37.56% vs 6.97% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "49.70",
          "val2": "17.50",
          "chgp": "184.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-45.40",
          "val2": "-70.50",
          "chgp": "35.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.10",
          "val2": "3.00",
          "chgp": "3.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.20",
          "val2": "-7.80",
          "chgp": "-17.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-51.70",
          "val2": "-82.80",
          "chgp": "37.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-920.70%",
          "val2": "-4,497.50%",
          "chgp": "357.68%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'23 - YoYstock-summary
Jun'23
Jun'22
Change(%)
Net Sales
8.30
8.40
-1.19%
Operating Profit (PBDIT) excl Other Income
-8.00
-15.00
46.67%
Interest
0.00
1.00
-100.00%
Exceptional Items
-16.20
4.20
-485.71%
Consolidate Net Profit
-23.90
-12.10
-97.52%
Operating Profit Margin (Excl OI)
-983.40%
-1,790.20%
80.68%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2023 is -1.19% vs -26.96% in Jun 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2023 is -97.52% vs 45.00% in Jun 2022

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
49.70
17.50
184.00%
Operating Profit (PBDIT) excl Other Income
-45.40
-70.50
35.60%
Interest
3.10
3.00
3.33%
Exceptional Items
-9.20
-7.80
-17.95%
Consolidate Net Profit
-51.70
-82.80
37.56%
Operating Profit Margin (Excl OI)
-920.70%
-4,497.50%
357.68%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 184.00% vs -37.05% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 37.56% vs 6.97% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About RVL Pharmaceuticals Plc stock-summary
stock-summary
RVL Pharmaceuticals Plc
Pharmaceuticals & Biotechnology
Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company. The Company is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The Company sells portfolio products consisting of promoted products and non-promoted products, which incorporate its Osmodex drug delivery system. The Company’s Osmodex drug delivery system uses osmotic pressure to provide a controlled drug release and is adaptable to many different combinations of immediate-release, extended-release and controlled- or delayed-release formulations that contain one or more drugs. The Company’s non-promoted product portfolio includes methylphenidate ER and venlafaxine extended-release tablets (VERT) as well as ANDAs and prescription dietary supplements. Its promoted products are led by Divigel and M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg).
Company Coordinates stock-summary
Company Details
400 Crossing Blvd , BRIDGEWATER NJ : 08807-2863
stock-summary
Tel: 1 908 80913001 212 4522729
stock-summary
http://www.osmotica.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."